Intralesional

• Intralesional therapy involves injecting medication directly into a lesion for targeted treatment.
• This approach delivers high concentrations of therapeutic agents precisely where needed, reducing systemic side effects.
• Commonly used agents include corticosteroids, chemotherapy drugs, and immunotherapies.
• It is effective for various conditions, including dermatological issues, certain cancers, and inflammatory disorders.
• The mechanism relies on direct action within the lesion, targeting specific cells or pathways responsible for the disease.

What is Intralesional: Definition and Approach

Intralesional refers to a medical procedure where a therapeutic substance is injected directly into a lesion or an area of diseased tissue. This targeted delivery method ensures that the medication reaches the affected site in high concentrations, which can be particularly beneficial for conditions that are localized and accessible. An intralesional injection is the specific act of performing this direct administration.

The primary advantage of this approach, which forms the core of the intralesional treatment definition, is its ability to provide potent local effects while often reducing the systemic side effects associated with oral or intravenous administration. By concentrating the drug within the lesion, clinicians can achieve therapeutic outcomes with lower overall doses, leading to a more favorable safety profile for many patients. This precision makes intralesional therapy a valuable tool in various medical specialties, particularly dermatology and oncology.

How Intralesional Injections Work

Intralesional injections work by delivering therapeutic agents directly into the pathological tissue, allowing for a concentrated and localized effect. This direct delivery bypasses the systemic circulation for initial distribution, meaning the medication acts precisely at the site of the lesion. The mechanism often involves the active substance interacting with specific cells or pathways within the diseased tissue, such as reducing inflammation, inhibiting cell proliferation, or stimulating an immune response.

For instance, when corticosteroids are injected intralesionally, they exert potent anti-inflammatory and immunosuppressive effects directly within the lesion, helping to shrink or resolve it. In cases of certain skin cancers, intralesional chemotherapy or immunotherapy agents can directly target and destroy cancer cells or activate the body’s immune system to fight the tumor. This localized action is crucial for maximizing efficacy while minimizing exposure to healthy tissues elsewhere in the body.

Common Intralesional Therapy Uses

Intralesional therapy uses are diverse, spanning various medical conditions where localized treatment is advantageous. This approach is particularly effective for dermatological conditions, certain types of cancer, and inflammatory disorders. The direct delivery of medication allows for targeted action against specific pathologies.

Some of the common applications include:

• Dermatological Conditions:
  • Keloids and Hypertrophic Scars: Intralesional corticosteroids are a first-line treatment to reduce inflammation and collagen production, helping to flatten and soften these raised scars.
  • Alopecia Areata: Corticosteroids injected directly into affected scalp areas can suppress the immune response attacking hair follicles, promoting hair regrowth.
  • Psoriasis: Localized plaques can be treated with intralesional corticosteroids to reduce inflammation and scaling.
  • Warts (Verrucae): Immunotherapy agents or specific chemotherapeutic drugs can be injected to stimulate an immune response or directly destroy wart tissue.
• Certain Cancers:
  • Melanoma and Basal Cell Carcinoma: Intralesional immunotherapy (e.g., talimogene laherparepvec for melanoma) or chemotherapy agents can be used for accessible tumors, particularly when surgery is not feasible or to enhance systemic treatment.
  • Cutaneous T-cell Lymphoma: Direct injection of certain agents can help manage localized skin lesions.

According to data from the American Academy of Dermatology, intralesional corticosteroids are a cornerstone in the management of keloids, which affect approximately 5-15% of individuals with darker skin types, highlighting the significant role of this therapy in clinical practice.